{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-110789","form_type":"8-K","ticker":"ZURA","cik":"0001855644","company_name":"Zura Bio Ltd","filed_at":"2025-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.836445+00:00","generated_at":"2026-05-16T20:36:06.342009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"confidence":"high","headline":"Zura Bio reports Q3 2025 net loss of $20.0M; cash $139M to fund through 2027","bullets":["Net loss $20.0M ($0.21/sh) vs $22.9M ($0.26/sh) in Q3 2024; R&D spend rose to $11.9M as Phase 2 trials advanced.","Cash and equivalents $139.0M as of Sep 30, 2025; company expects to fund planned operations through 2027.","Phase 2 trials tibulizumab: TibuSHIELD (HS) topline Q3 2026; TibuSURE (SSc) topline Q4 2026.","G&A expenses decreased to $7.6M from $13.3M, driven by prior-year one-time non-cash share-based comp.","No revenue reported; clinical-stage immunology company with no approved products."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-110789","json":"https://secwatch.observer/filing/0001104659-25-110789.json","markdown":"https://secwatch.observer/filing/0001104659-25-110789.md","text":"https://secwatch.observer/filing/0001104659-25-110789.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/0001104659-25-110789-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855644/000110465925110789/tm2531128d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T20:36:06.342009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}